Schedule of Summarizes Information About Stock Options (Details) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($) $ / shares shares
2014 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Stock Options Outstanding, Beginning Balance | shares	11,568,655
Weighted Average Exercise Price, Beginning Balance | $ / shares	$ 2.71
Remaining Contractual Term (Years)	7 years 4 months 24 days
Intrinsic Value Outstanding, Beginning Balance | $		[1]
Number of Stock Options, Granted | shares	7,280,000	[2]
Weighted Average Exercise Price, Granted | $ / shares	$ 0.48	[2]
Number of Stock Option, Exercised | shares
Weighted Average Exercise Price, Exercised | $ / shares
Number of Stock Option, Forfeited | shares	(1,326,249)
Weighted Average Exercise Price, Forfeited | $ / shares	$ 1.87
Number of Stock Options Outstanding, Ending Balance | shares	17,522,406	[3]
Weighted Average Exercise Price, Ending Balance | $ / shares	$ 1.85	[3]
Remaining Contractual Term (Years)	7 years 10 months 24 days	[3]
Intrinsic Value Outstanding, Ending Balance | $	$ 7	[1],[3]
Number of Stock Options Vested and exercisable stock options | shares	7,998,032
Weighted Average Exercise Price, Vested and exercisable stock options | $ / shares	$ 2.92
Remaining Contractual Term (Years), Vested and exercisable stock options	6 years 2 months 12 days
Intrinsic Value Exercisable, Ending Balance | $		[1]
2018 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Stock Options Outstanding, Beginning Balance | shares	2,565,377
Weighted Average Exercise Price, Beginning Balance | $ / shares	$ 3.14
Remaining Contractual Term (Years)	8 years 3 months 18 days
Intrinsic Value Outstanding, Beginning Balance | $	$ 428	[4]
Number of Stock Options, Granted | shares	2,732,500	[5]
Weighted Average Exercise Price, Granted | $ / shares	$ 1.31	[5]
Number of Stock Option, Exercised | shares
Weighted Average Exercise Price, Exercised | $ / shares
Number of Stock Option, Forfeited | shares	(347,915)
Weighted Average Exercise Price, Forfeited | $ / shares	$ 2.57
Number of Stock Options Outstanding, Ending Balance | shares	4,949,962	[6]
Weighted Average Exercise Price, Ending Balance | $ / shares	$ 2.17	[6]
Remaining Contractual Term (Years)	8 years 8 months 12 days	[6]
Intrinsic Value Outstanding, Ending Balance | $	$ 641	[4],[6]
Number of Stock Options Vested and exercisable stock options | shares	1,374,179
Weighted Average Exercise Price, Vested and exercisable stock options | $ / shares	$ 2.76
Remaining Contractual Term (Years), Vested and exercisable stock options	6 years 10 months 24 days
Intrinsic Value Exercisable, Ending Balance | $	$ 440	[4]

[1] The intrinsic value is computed as the difference between the quoted price of the PAVmed common stock on each of June 30, 2023 and December 31, 2022 and the exercise price of the underlying PAVmed stock options, to the extent such quoted price is greater than the exercise price.

[2] Stock options granted under the PAVmed 2014 Equity Plan and those granted outside such plan generally vest one-third in one year then ratably over the next eight quarters, and have a ten-year contractual term from date-of-grant.

[3] The outstanding stock options presented in the table above, are inclusive of 500,854 stock options granted outside the PAVmed 2014 Equity Plan, as of June 30, 2023 and December 31, 2022.

[4] The intrinsic value is computed as the difference between the quoted price of the Lucid Diagnostics common stock on each of June 30, 2023 and December 31, 2022 and the exercise price of the underlying Lucid Diagnostics stock options, to the extent such quoted price is greater than the exercise price.

[5] Stock options granted under the Lucid Diagnostics 2018 Equity Plan and those granted outside such plan generally vest one-third in one year then ratably over the next eight quarters, and have a ten-year contractual term from date-of-grant.

[6] The outstanding stock options presented in the table above, are inclusive of 423,300 stock options granted outside the Lucid Diagnostics 2018 Equity Plan, as of June 30, 2023 and December 31, 2022.